Trial Profile
A phase 3 study of ISIS-TTRrx in Familial Amyloid Polyneuropathy (FAP).
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- 24 Apr 2015 New trial record